PBM Stock Forecast: Psyence Biomedical Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 4 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Psyence Biomedical Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (31): The shares have been drifting up relative to others.
Accruals (5): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PBM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PBM, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
PBM appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PBM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.4×
- EV / EBITDA
- —
Cheaper than 89% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −58.6%
- Return on assets
- −31.3%
- Dividend yield
- —
Higher than 20% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Psyence Biomedical Ltd. has a market value of $11.3M and an enterprise value of $2.1M.
Psyence Biomedical Ltd. employs 12 people.
Data provided by Twelve Data
PBM and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PBM’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Psyence Biomedical Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PBM
How does Ticker Nerd's model rank PBM?
As at 21 Nov 2026, Psyence Biomedical Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (31 of 100).
What is the PBM stock forecast for 2030?
No analyst covering Psyence Biomedical Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBM are extrapolating price history, which says nothing about the business.
What does Psyence Biomedical Ltd. do?
Psyence Biomedical Ltd. is a Toronto-based biopharmaceutical company focused on developing botanical psilocybin-based medicines for mental health and palliative care settings. The company’s current work centers on nature-derived psychedelic therapeutics designed to address unmet needs in conditions such as adjustment disorder, anxiety, depression, grief, and related psychological distress in patients facing serious illness.
About Psyence Biomedical Ltd.
Psyence Biomedical Ltd. is a Toronto-based biopharmaceutical company focused on developing botanical psilocybin-based medicines for mental health and palliative care settings. The company’s current work centers on nature-derived psychedelic therapeutics designed to address unmet needs in conditions such as adjustment disorder, anxiety, depression, grief, and related psychological distress in patients facing serious illness. Its lead candidate is being evaluated in clinical studies as a capsule formulation of naturally sourced psilocybin, reflecting the company’s emphasis on standardized, non-synthetic drug development. Psyence Biomedical operates within the broader life sciences and healthcare markets, combining drug development, clinical research, and commercialization efforts around psychedelic medicine. Through this specialization, the company occupies a niche position in the emerging field of evidence-based psychedelic therapeutics, with a focus on supportive care applications rather than general consumer health products.
CEO Mr. Jody Aufrichtig · 12 employees · Canada · https://psyencebiomed.com